Inflation Reduction Act Likely to Shape Specialty Prescribing Decisions in 2025, According to Spherix Global Insights
Spherix Global Insights Announces New Study on Impact of Inflation Reduction Act (IRA) on Specialty Practices and Key Insights for Biopharmaceutical Companies in 2025. Exton, PA., December 10, 2024 – In 2022, the U.S. Congress enacted the Inflation Reduction Act (IRA), a landmark piece of legislation aimed at addressing various national priorities, including the reduction […]
Cleanup for the IL-23 class in ulcerative colitis as new drugs ‘rapidly gained significant momentum’: report
Spherix Global Insights notes that differentiation among the IL-23 therapies “will be essential” as Tremfya and Omvoh look to battle class front-runner Skyrizi. (AbbVie) The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly growing into the established UC market as this IL-23 inhibitor class of […]
Tremfya’s Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
Future intensified intra-class competition among Omvoh, Skyrizi and Tremfya is expected as each brand attempts differentiation. Exton, PA., November 15, 2024 – In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson & Johnson’s Tremfya now joining AbbVie’s […]
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the Horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. According to Spherix analysts, Rezdiffra “has seen rapid uptake,” with more than 60% of gastroenterologists and hepatologists surveyed in October 2024 by Spherix “indicating that […]
AbbVie’s Skyrizi leapfrogs Lilly’s Omvoh to take early lead in IL-23 colitis space: survey
AbbVie now faces a more seasoned rival than Eli Lilly. (AbbVie) Spherix Global Insights said AbbVie’s Skyrizi has quickly blasted past Eli Lilly’s Omvoh in ulcerative colitis, capturing more than double the market share of its rival two months after launch. But AbbVie now faces another challenger, with Spherix predicting a similarly speedy launch for Johnson & […]
Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
With Tremfya also securing approval in UC earlier this month, competition promises to be fierce among the IL-23s, according to Spherix Global Insights. Exton, PA., October 1, 2024 – The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA approval. In June, […]
Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 rheumatologists, and 106 dermatologists), to provide an updated perspective on adalimumab biosimilar […]
Ipsen’s Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead’s Livdelzi
Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Exton, PA., August 28, 2024 – – The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of […]
Docs embrace Takeda’s Eohilia, creating competition for Sanofi, Regeneron’s blockbuster Dupixent
Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent and is delaying the use of Regeneron and Sanofi’s big blockbuster drug. The FDA rejected Eohilia, which Takeda called TAK-721 during development, in the chronic inflammatory disease eosinophilic esophagitis in […]
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses. EXTON, PA., July 18, 2024 – In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic esophagitis (EoE) in patients aged 11 and older. This […]
